One drug now carries the whole story
- Immunovant has no approved products and has not generated revenue to date.
- After two Phase 3 failures in thyroid eye disease, the company stopped all batoclimab development.
- The company is now a pure bet on IMVT-1402 across six autoimmune disease programs.
- Cash and cash equivalents were $902.1 million at March 31, 2026, which management says can fund work through a possible first IMVT-1402 launch in Graves' Disease.
- The next key data are expected from cutaneous lupus and difficult-to-treat rheumatoid arthritis in the second half of calendar 2026.
A cleaner but riskier bet
Immunovant used to have two active drugs in the story. That changed in April 2026 when batoclimab failed two Phase 3 studies in thyroid eye disease. The company stopped all batoclimab development as a result.
The bull case is now tied entirely to IMVT-1402. This drug may be a better anti-FcRn treatment because it is designed to lower harmful IgG antibodies with less effect on albumin and LDL cholesterol. In May 2026, early data in rheumatoid arthritis showed strong response rates, which gave the company its first proof that IMVT-1402 works in patients.
The bear case is simple. One drug now carries nearly all of the company value. A setback in IMVT-1402, a delay across the trial plan, or a safety problem would hurt the whole thesis at once.
The balance sheet gives the company room to try. Immunovant reported $902.1 million in cash at March 31, 2026. Management says this can fund announced programs through a possible first commercial launch of IMVT-1402 in Graves' Disease. That lowers near-term financing risk, but clinical risk remains high.
No sales until approval
Immunovant is a pre-revenue biotech. It does not sell any medicine today. Its value depends on running clinical trials, getting regulators to approve IMVT-1402, and then selling or partnering the drug.
The company funds itself through stock offerings, not product cash flow. That is common for clinical-stage biotech, but it means shareholders face dilution if trials take longer or cost more than planned.
The possible moat is the drug profile and the patents around it. IMVT-1402 is given under the skin and targets FcRn, a receptor that helps IgG antibodies stay in the body. Blocking FcRn can lower IgG, which may help diseases where IgG antibodies attack healthy tissue.
The model breaks easily. If IMVT-1402 cannot show strong benefit and clean safety in late-stage trials, there is no second active drug program to rely on.
IMVT-1402 takes center stage
IMVT-1402 in Graves' Disease
This is the lead commercial target. Immunovant expects top-line results from the IMVT-1402 Graves' Disease trials in 2027.
IMVT-1402 in difficult-to-treat rheumatoid arthritis
This program tests whether FcRn blockade can help patients whose rheumatoid arthritis has been hard to control. Period 1 open-label top-line results are expected in the second half of calendar 2026.
IMVT-1402 in myasthenia gravis
Myasthenia gravis is already a proven anti-FcRn market for other companies. Immunovant expects IMVT-1402 top-line results in MG in 2027.
IMVT-1402 in chronic inflammatory demyelinating polyneuropathy
CIDP is a nerve disease where lowering harmful antibodies may help. Immunovant expects top-line results from this trial in 2028.
IMVT-1402 in Sjögren's disease
This is a potentially registrational program that started in June 2025. Top-line results are expected in 2028.
IMVT-1402 in cutaneous lupus erythematosus
This is a proof-of-concept trial, meaning it is meant to show whether the idea works before a larger approval trial. Top-line results are expected in the second half of calendar 2026.
Batoclimab
Batoclimab is no longer an active development program. Immunovant stopped all work on it after two Phase 3 thyroid eye disease studies missed their primary goals.
One research company
For fiscal 2026, Immunovant did not report revenue segments because it had no commercial products and had not generated revenue to date. The practical mix is all research and development activity.
What could break the thesis
Single-asset dependence
High impact · Medium oddsImmunovant is now almost fully tied to IMVT-1402. That focus can help execution, but it also means a bad safety signal or weak efficacy result would damage the whole company. Batoclimab is no longer a backup program.
Interim data reliance
High impact · Medium oddsThe recent rheumatoid arthritis data was an early look at an open-label trial. Findings could change when all data are fully analyzed and audited. A negative shift in final results would damage confidence in the drug.
HanAll partnership dispute
Medium impact · Medium oddsImmunovant licenses key assets from HanAll. The 2026 10-K says HanAll may disagree with Immunovant's actions on batoclimab, and that the matter could lead to arbitration or litigation. A settlement or dispute could create cost, delay, or distraction.
Manufacturing and BIOSECURE Act risk
Medium impact · Medium oddsThe BIOSECURE Act could restrict the use of some foreign contract manufacturers if they are named as biotechnology companies of concern. If any Immunovant supplier is affected, the company may need to move manufacturing, which is costly and slow.
FcRn competition
High impact · High oddsThe anti-FcRn field is crowded. Immunovant has named competitors including argenx, Johnson & Johnson, and UCB, with approved or late-stage assets in related diseases. IMVT-1402 must show enough safety, efficacy, or convenience to win market share.
Future dilution
Medium impact · Low oddsManagement says current cash can fund announced programs through a possible first IMVT-1402 launch in Graves' Disease. Still, delays, extra trials, litigation, or manufacturing changes could force another equity raise.
In one breath
Does Immunovant have any approved drugs?
No. Immunovant has no approved commercial product and has not generated revenue to date. The company depends on clinical trial success and future regulatory approvals.
What happened to batoclimab?
Batoclimab failed two Phase 3 studies in thyroid eye disease in April 2026. Immunovant then stopped all development of batoclimab and shifted its focus to IMVT-1402.
What is the next major Immunovant catalyst?
The next expected readouts are from IMVT-1402 in cutaneous lupus erythematosus and difficult-to-treat rheumatoid arthritis. Both are expected in the second half of calendar 2026.
Why does IMVT-1402 matter so much?
IMVT-1402 is now the company's sole active drug asset. It is being tested across six autoimmune disease programs, so strong data could create a large opportunity, while weak data would hurt the whole thesis.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Immunovant, Inc. in Finn's Biotechnology industry ranking.
